Transgene Biotek Limited (BOM:526139)
India · Delayed Price · Currency is INR 3.110
-0.020 (-0.64%)
At close: Jun 5, 2026
Transgene Biotek Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2.11 | 2.61 | 2.35 | 0.55 | 0.87 |
Other Revenue | 1.5 | - | - | - | - |
| 3.61 | 2.61 | 2.35 | 0.55 | 0.87 | |
Revenue Growth (YoY) | 38.51% | 10.98% | 326.32% | -36.44% | -48.87% |
Cost of Revenue | - | - | 0.03 | 0.66 | -0.45 |
Gross Profit | 3.61 | 2.61 | 2.32 | -0.11 | 1.32 |
Selling, General & Admin | 1.47 | 3.15 | 3.18 | 3.04 | 2.93 |
Other Operating Expenses | 6.07 | 10.68 | 5.2 | 7.38 | 3 |
Operating Expenses | 9.54 | 14.77 | 9.3 | 59.91 | 105.17 |
Operating Income | -5.93 | -12.16 | -6.98 | -60.03 | -103.85 |
Interest Expense | -10.6 | -2.44 | -1.4 | -1.81 | -2.29 |
Other Non Operating Income (Expenses) | - | 1.75 | 1.75 | 1.75 | 1.75 |
EBT Excluding Unusual Items | -16.53 | -12.84 | -6.63 | -60.09 | -104.39 |
Other Unusual Items | - | 6.08 | 0.07 | - | 0.37 |
Pretax Income | -16.53 | -6.76 | -6.56 | -60.09 | -104.02 |
Net Income | -16.53 | -6.76 | -6.56 | -60.09 | -104.02 |
Net Income to Common | -16.53 | -6.76 | -6.56 | -60.09 | -104.02 |
Shares Outstanding (Basic) | 75 | 76 | 76 | 76 | 76 |
Shares Outstanding (Diluted) | 75 | 76 | 76 | 76 | 76 |
Shares Change (YoY) | -0.84% | - | - | - | - |
EPS (Basic) | -0.22 | -0.09 | -0.09 | -0.79 | -1.37 |
EPS (Diluted) | -0.22 | -0.09 | -0.09 | -0.79 | -1.37 |
Free Cash Flow | -0.11 | -5.04 | 0.05 | -0.01 | 0.98 |
Free Cash Flow Per Share | -0.00 | -0.07 | 0.00 | - | 0.01 |
Gross Margin | 100.00% | 100.00% | 98.72% | -20.33% | 152.09% |
Operating Margin | -164.14% | -466.40% | -297.32% | -10894.01% | -11979.30% |
Profit Margin | -457.74% | -259.34% | -279.06% | -10904.90% | -11998.40% |
Free Cash Flow Margin | -3.13% | -193.21% | 1.96% | -2.36% | 112.81% |
EBITDA | -3.94 | -11.23 | -6.06 | -10.53 | -4.61 |
EBITDA Margin | -109.00% | - | -258.02% | - | - |
D&A For EBITDA | 1.99 | 0.93 | 0.92 | 49.5 | 99.24 |
EBIT | -5.93 | -12.16 | -6.98 | -60.03 | -103.85 |
EBIT Margin | -164.14% | - | -297.32% | - | - |
Revenue as Reported | 3.61 | 10.44 | 4.18 | 2.31 | 2.99 |
Advertising Expenses | - | 0.01 | 0.02 | 0.02 | 0.04 |